Answers are grounded in this paper and cite their sources.
Although the short-term results of targeted α-therapy (TAT) with ²²⁵Ac-DOTATATE in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have proven the therapy to be effective, to our knowledge no one has assessed the long-term outcome results. In this study, we aimed to evaluate the long-term outcome of ²²⁵Ac-DOTATATE TAT in patients with somatostatin receptor–expressing advanced-stage metastatic GEP-NETs. Methods: Patients with ⁶⁸Ga-DOTANOC PET/CT scans showing moderate-to-high somatostatin receptor expression were recruited. Systemic TAT was performed on 91 adults with GEP-NETs (54 men and 37 women; mean age, 54.3 y; range, 25–75 y) using ²²⁵Ac-DOTATATE (100–120 kBq/kg of body weight). All patients were given capecitabine therapy as a radiosensitizer (2 g/d) from days 0 to 14 of every ²²⁵Ac-DOTATATE treatment cycle. Patients were categorized into 3 groups based on the status of prior ¹⁷⁷Lu-peptide receptor radionuclide therapy (PRRT): a prior-¹⁷⁷Lu-PRRT–refractory group; a prior-¹⁷⁷Lu-PRRT disease-control group; and a ¹⁷⁷Lu-PRRT–naïve group. Primary endpoints were overall survival (OS), and secondary endpoints included progression-free survival (PFS), objective tumor response, clinical response, and assessment of treatment-related toxicities. Results: Among the 91 patients, 57 underwent prior ¹⁷⁷Lu-DOTATATE therapy (24 with controlled disease [partial response/stable disease] and 33 with progressive disease [PD]). In total, 453 ²²⁵Ac-DOTATATE TAT cycles were administered (median, 4 cycles per patient; range, 1–10) in a median follow-up of 24 mo (range, 5–41 mo). Median OS was not attained, with a 24-mo OS probability of 70.8%. In multivariate analysis, prognostic factors associated with a poor OS included the presence bone metastases (hazard ratio [HR], 2.501; 95% CI, 1.826–5.791; P < 0.032) and ²²⁵Ac-DOTATATE therapy–refractory disease (HR, 8.781; 95% CI, 3.843–20.062; P < 0.0001). Median PFS was also not reached, with a 24-mo PFS probability of 67.5%. The multivariate analysis revealed only ¹⁷⁷Lu-PRRT–refractory disease to be significantly associated with a reduced PFS (HR, 14.338; 95% CI, 1.853–97.698; P = 0.011). Two of 79 patients (2.5%) with assessable disease experienced a complete response, 38 (48%) had a partial response, 23 (29%) had stable disease, and 16 (20.2%) had PD. PD was observed in more patients from the prior-¹⁷⁷Lu-PRRT–refractory group (11/33, 34%) than in ¹⁷⁷Lu-PRRT–naïve patients (4/24, 11%; P = 0.056). Patients from the prior-¹⁷⁷Lu-PRRT–refractory group had the highest risk of poor PFS (HR, 13.553; 95% CI, 4.343–42.271; P = 0.0009). A significant clinical benefit was achieved after ²²⁵Ac-DOTATATE therapy with minimal treatment-related toxicities. Conclusion: In long-term results, ²²⁵Ac-DOTATATE TAT showed promise and improved the OS, even in patients refractory to prior ¹⁷⁷Lu-DOTATATE treatment, with transient and acceptable adverse effects.
No takes yet. Share an insight, caveat, or question.
Ballal et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: